New antisense oligonucleotide therapies reach first base in ALS
Crossref DOI link: https://doi.org/10.1038/s41591-021-01629-7
Published Online: 2022-01-24
Published Print: 2022-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lopez, Elia R. http://orcid.org/0000-0003-3867-1785
Borschel, William F.
Traynor, Bryan J.
Text and Data Mining valid from 2022-01-01
Version of Record valid from 2022-01-01
Article History
First Online: 24 January 2022
Competing interests
: B.J.T. holds the US, Canadian and European patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion in C9orf72.